PHASE-II STUDY OF 4'-(9-ACRIDINYLAMINO)METHANESULFON-META-ANISIDIDE (NSC 249992) IN CHILDREN WITH ACUTE-LEUKEMIA AND LYMPHOMA

  • 1 January 1982
    • journal article
    • research article
    • Vol. 42  (4) , 1579-1581
Abstract
Phase I clinical studies of 4''-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) using several dose schedules have shown acceptable toxicity and antitumor responses in acute leukemia and several carcinomas. Thirty-eight children with acute leukemia and non-Hodgkin''s lymphoma were treated with AMSA in a total dose of 140-600 mg/m given as a daily i.v. infusion in 2-5 days. Maximal tolerated dose was 600 mg/m2 given in 5 days. Complete and partial remissions were seen in 4 of 18 patients with acute lymphocytic leukemia, 0 of 8 patients with acute nonlymphocytic leukemia and 1 of 5 patients with non-Hodgkin''s lymphoma. Marrow aplasia and remissions were also seen with lower doses. The major toxic effects were mucositis, fever and sepsis which were dose related. Mild nausea and vomiting, transient elevation of serum glutamic oxaloacetic transaminase and bilirubin were noted. All of these patients had prior anthracycline therapy. Abnormal ECG were seen in 14 of 23 patients who had ECG done before and after AMSA. Seven developed congestive heart failure, in association with sepsis in 5 and with epicardial disease in 1. AMSA apparently possesses significant activity in childhood leukemia and lymphoma; studies of AMSA in combination with other effective agents should be done.